This is different because the entire case for BPC-157, as far as I can tell, boils down to I know someone who took it and was cured of something
BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
What Would Change This View A negative RCT in living skin If a properly powered randomized trial of at-home microinfusion with GHK-Cu versus matched topical control failed to show histologic or photographic differences at 12 weeks, that result would shift the position of this article from "biologically plausible recommendation" to "interesting hypothesis pending data." A safety signal in long-term at-home users If the consumer at-home microinfusion category began producing case reports of infection, scarring, or persistent dermal damage at rates higher than baseline microneedling, the depth recommendation would tighten or the route would be deprecated
10.32607/actanaturae.11610 107 KowluruR
But for any of these potential benefits to be studied accurately, the product itself must be flawless
Nrregaard PK, Deryabina MA, Tofteng Shelton P, Fog JU, Daugaard JR, Eriksson PO, et al
